Invion Ltd (AU:IVX) — Market Cap & Net Worth
Market Cap & Net Worth: Invion Ltd (IVX)
Invion Ltd (AU:IVX) has a market capitalization of $2.36 Million (AU$3.34 Million) as of September 22, 2026. Listed on the AU stock exchange, this Australia-based company holds position #29894 globally and #1733 in its home market, demonstrating a -2.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Invion Ltd's stock price AU$0.04 by its total outstanding shares 85647255 (85.65 Million). Also see Invion Ltd (IVX) total assets for a full breakdown of the balance sheet.
Invion Ltd Market Cap History: 2015 to 2026
Invion Ltd's market capitalization history from 2015 to 2026. Data shows change from $28.71 Million to $2.36 Million (-25.33% CAGR). Also see Invion Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Invion Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Invion Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check IVX share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.59x
Invion Ltd's market cap is 4.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $9.57 Million | $139.10K | -$4.45 Million | 68.79x | N/A |
| 2018 | $109.08 Million | $737.71K | -$926.51K | 147.86x | N/A |
| 2019 | $78.78 Million | $3.88 Million | -$2.55 Million | 20.29x | N/A |
| 2020 | $60.60 Million | $3.48 Million | -$953.89K | 17.43x | N/A |
| 2021 | $127.26 Million | $2.33 Million | -$1.48 Million | 54.62x | N/A |
| 2022 | $54.54 Million | $3.29 Million | -$2.24 Million | 16.57x | N/A |
| 2023 | $30.30 Million | $4.10 Million | -$1.61 Million | 7.38x | N/A |
| 2024 | $16.97 Million | $3.69 Million | -$5.63 Million | 4.59x | N/A |
Competitor Companies of IVX by Market Capitalization
Companies near Invion Ltd in the global market cap rankings as of September 22, 2026. Review IVX goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Invion Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #521 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #596 globally with a market cap of $45.64 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #638 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #648 globally with a market cap of $42.98 Billion USD ( CN¥293.69 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #521 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #596 | GALDERMA GROUP AG | NYSE:GALDY | $45.64 Billion | $39.14 |
| #638 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.30 |
| #648 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.98 Billion | CN¥46.04 |
Invion Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Invion Ltd's market cap moved from $28.71 Million to $ 2.36 Million, with a yearly change of -25.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$2.36 Million | -58.06% |
| 2025 | AU$5.64 Million | -66.79% |
| 2024 | AU$16.97 Million | -44.00% |
| 2023 | AU$30.30 Million | -44.44% |
| 2022 | AU$54.54 Million | -57.14% |
| 2021 | AU$127.26 Million | +110.00% |
| 2020 | AU$60.60 Million | -23.08% |
| 2019 | AU$78.78 Million | -27.78% |
| 2018 | AU$109.08 Million | +279.91% |
| 2017 | AU$28.71 Million | +200.06% |
| 2016 | AU$9.57 Million | -66.67% |
| 2015 | AU$28.71 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 22nd, 2026 the market cap of Invion Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.36 Million USD |
| MoneyControl | $2.36 Million USD |
| MarketWatch | $2.36 Million USD |
| marketcap.company | $2.36 Million USD |
| Reuters | $2.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Invion Ltd
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more